# Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

> **NCT01580618** · PHASE2,PHASE3 · TERMINATED · sponsor: **Kaiser Permanente** · enrollment: 20 (actual)

## Conditions studied

- Pleural Effusion

## Interventions

- **DRUG:** normal saline
- **DRUG:** TNK (Tenecteplase)

## Key facts

- **NCT ID:** NCT01580618
- **Lead sponsor:** Kaiser Permanente
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Unable to accrue patients at a reasonable rate
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01580618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01580618, "Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01580618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*